We found that AS1842856 treatment for 48 h induced FAS and/or BIM gene expression in BT549, MDA‐MB‐468 breast cancer cell lines, and DBTRG, A172 LN229, LN18, and U87MG GBM cell lines (Fig. 3A–F and Fig. S1A). This evidence concerns the gene BCL2L11 and glioblastoma.